Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non–small cell lung cancer: KEYNOTE-782

彭布罗利珠单抗 医学 培美曲塞 卡铂 肺癌 肿瘤科 化疗 内科学 实体瘤疗效评价标准 代理终结点 癌症 顺铂 进行性疾病 免疫疗法
作者
Jair Bar,Emilio Esteban,Delvys Rodríguez‐Abreu,Santiago Ponce-Aix,Zsuzsanna Szalai,Enriqueta Felip,Maya Gottfried,Mariano Provencio,Andrew Robinson,Andrea Fülöp,Suman Bannur Rao,D. Ross Camidge,Giovanna Speranza,Steven Matthew Townson,Julie Kobie,Mark Ayers,Elisha J. Dettman,Nathan M. Hunkapiller,Robert McDaniel,Byoungsok Jung
出处
期刊:Lung Cancer [Elsevier BV]
卷期号:190: 107506-107506 被引量:7
标识
DOI:10.1016/j.lungcan.2024.107506
摘要

BACKGROUND: First-line pembrolizumab plus chemotherapy has shown clinical benefit in patients with metastatic non-small cell lung cancer (NSCLC) regardless of tissue tumor mutational burden (tTMB) status. Blood tumor mutational burden (bTMB), assessed using plasma-derived circulating tumor DNA (ctDNA), may be a surrogate for tTMB. The KEYNOTE-782 study evaluated the correlation of bTMB with the efficacy of first-line pembrolizumab plus chemotherapy in NSCLC. METHODS: for 4 cycles, then pembrolizumab plus pemetrexed for ≤31 additional cycles every 3 weeks. Study objectives were to evaluate the association of baseline bTMB with objective response rate (ORR) (RECIST v1.1 by investigator assessment; primary), progression-free survival (PFS; RECIST v1.1 by investigator assessment), overall survival (OS), and adverse events (AEs; all secondary). A next-generation sequencing assay (GRAIL LLC) with a ctDNA panel that included lung cancer-associated and immune gene targets was used to measure bTMB. RESULTS: 117 patients were enrolled; median time from first dose to data cutoff was 19.3 months (range, 1.0-35.5). ORR was 40.2 % (95 % CI 31.2-49.6 %), median PFS was 7.2 months (95 % CI 5.6-9.8) and median OS was 18.1 months (95 % CI 13.5-25.6). Treatment-related AEs occurred in 113 patients (96.6 %; grade 3-5, n = 56 [47.9 %]). Of patients with evaluable bTMB (n = 101), the area under the receiver operating characteristics curve for continuous bTMB to discriminate response was 0.47 (95 % CI 0.36-0.59). Baseline bTMB was not associated with PFS or OS (posterior probabilities of positive association: 16.8 % and 7.8 %, respectively). CONCLUSIONS: AEs were consistent with the established safety profile of first-line pembrolizumab plus chemotherapy in NSCLC. Baseline bTMB did not show evidence of an association with efficacy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
正直的又柔完成签到,获得积分10
刚刚
无花果的应助被yyy采纳,获得10
1秒前
香蕉觅云的应助被鹿lu采纳,获得10
2秒前
共享精神的应助被云岚采纳,获得10
2秒前
余漆完成签到,获得积分10
2秒前
华仔的应助被立菠萝采纳,获得10
3秒前
望除完成签到,获得积分0
3秒前
4秒前
4秒前
5秒前
天天快乐的应助被优乐美采纳,获得10
5秒前
5秒前
Lilii发布了新的文献求助10
5秒前
5秒前
6秒前
共享精神的应助被AAA采纳,获得10
6秒前
6秒前
星星完成签到,获得积分10
6秒前
DMUXLW完成签到,获得积分10
6秒前
水牛完成签到,获得积分10
7秒前
852的应助被quan采纳,获得10
8秒前
上官若男的应助被嘻嘻采纳,获得10
8秒前
JamesPei的应助被东东大王采纳,获得10
8秒前
8秒前
9秒前
伊啊亚发布了新的文献求助10
10秒前
10秒前
10秒前
摩奥锚发布了新的文献求助10
11秒前
11秒前
星月发布了新的文献求助10
11秒前
1752795896发布了新的文献求助10
11秒前
lmy发布了新的文献求助10
12秒前
13秒前
少年维特发布了新的文献求助20
13秒前
挞挞黄发布了新的文献求助10
13秒前
已知完成签到,获得积分20
15秒前
微笑听芹发布了新的文献求助10
15秒前
fantasy的应助被Lik采纳,获得10
15秒前
赘婿的应助被我要吃饭采纳,获得10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163922
求助须知:如何正确求助?哪些是违规求助? 9557995
关于积分的说明 21743022
捐赠科研通 7754548
什么是DOI,文献DOI怎么找? 3428401
关于科研通互助平台的介绍 2553053
邀请新用户注册赠送积分活动 2473008